You are here

JCI Insight DOI:10.1172/jci.insight.122109

Tumor fraction in cell-free DNA as a biomarker in prostate cancer.

Publication TypeJournal Article
Year of Publication2018
AuthorsChoudhury, AD, Werner, L, Francini, E, Wei, XX, Ha, G, Freeman, SS, Rhoades, J, Reed, SC, Gydush, G, Rotem, D, Lo, C, Taplin, M-E, Harshman, LC, Zhang, Z, O'Connor, EP, Stover, DG, Parsons, HA, Getz, G, Meyerson, M, J Love, C, Hahn, WC, Adalsteinsson, VA
JournalJCI Insight
Volume3
Issue21
Date Published2018 Nov 02
ISSN2379-3708
Abstract

BACKGROUND: Tumor content in circulating cell-free DNA (cfDNA) is a promising biomarker, but longitudinal dynamics of tumor-derived and non-tumor-derived cfDNA through multiple courses of therapy have not been well described.

METHODS: CfDNA from 663 plasma samples from 140 patients with castration-resistant prostate cancer (CRPC) was subject to sparse whole genome sequencing. Tumor fraction (TFx) estimated using the computational tool ichorCNA was correlated with clinical features and responses to therapy.

RESULTS: TFx associated with the number of bone metastases (median TFx = 0.014 with no bone metastases, 0.047 with 1-3 bone metastases, 0.190 for 4+ bone metastases; P < 0.0001) and with visceral metastases (P < 0.0001). In multivariable analysis, TFx remained associated with metastasis location (P = 0.042); TFx was positively correlated with alkaline phosphatase (P = 0.0227) and negatively correlated with hemoglobin (Hgb) (P < 0.001), but it was not correlated with prostate specific antigen (PSA) (P = 0.75). Tumor-derived and non-tumor-derived cfDNA track together and do not increase with generalized tissue damage from chemotherapy or radiation at the time scales examined. All new treatments that led to ≥30% PSA decline at 6 weeks were associated with TFx decline when baseline TFx was >7%; however, TFx in patients being subsequently maintained on secondary hormonal therapy was quite dynamic.

CONCLUSION: TFx correlates with clinical features associated with overall survival in CRPC, and TFx decline is a promising biomarker for initial therapeutic response.

TRIAL REGISTRATION: Dana-Farber/Harvard Cancer Center (DF/HCC) protocol no. 18-135.

FUNDING: Wong Family Award in Translational Oncology, Dana Farber Cancer Institute Medical Oncology grant, Gerstner Family Foundation, Janssen Pharmaceuticals Inc., and Koch Institute Support (core) grant P30-CA14051 from the National Cancer Institute (NCI).

DOI10.1172/jci.insight.122109
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/30385733?dopt=Abstract

Alternate JournalJCI Insight
PubMed ID30385733